Related Experiment Video
Updated: May 6, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
36.1K
PNPLA3 I148M polymorphism and progressive liver disease.
Paola Dongiovanni1, Benedetta Donati, Roberta Fares
1Paola Dongiovanni, Benedetta Donati, Roberta Fares, Rosa Lombardi, Luca Valenti, Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Policlinico Milano, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milano, Italy.
World Journal of Gastroenterology
|November 14, 2013
Summary
The patatin-like phospholipase domain-containing 3 (PNPLA3) I148M variant significantly impacts liver fat and fibrosis progression. This genetic factor influences various liver conditions, highlighting PNPLA3
Area of Science:
- Genetics and Molecular Biology
- Hepatology and Gastroenterology
- Metabolic and Lipid Disorders
Background:
- The patatin-like phospholipase domain-containing 3 (PNPLA3) protein plays a crucial role in hepatic lipid metabolism.
- A specific variant, Isoleucine 148 to Methionine (I148M), has emerged as a significant genetic determinant of liver fat accumulation.
- This PNPLA3 variant is associated with an increased risk and severity of various liver diseases.
Purpose of the Study:
- To elucidate the role of the PNPLA3 I148M variant in the pathogenesis of liver diseases.
- To investigate the impact of the I148M variant on the spectrum of liver damage, including steatosis, steatohepatitis, and fibrosis.
- To explore the potential of the I148M polymorphism as a general modifier of fibrogenesis across different liver conditions.
Main Methods:
- Review and synthesis of existing studies investigating the PNPLA3 I148M variant and its association with liver fat content and disease progression.
- Analysis of the variant's influence on alcohol-related liver disease, chronic hepatitis C, chronic hepatitis B, hereditary hemochromatosis, and primary sclerosing cholangitis.
- Examination of the independent effects of the I148M variant on fibrosis, steatosis, and inflammation.
Main Results:
- The PNPLA3 I148M variant is a major determinant of liver fat content and predisposes individuals to the full spectrum of fatty liver disease.
- This variant significantly influences the progression of alcohol-related steatohepatitis to cirrhosis and impacts fibrogenesis in other chronic liver diseases.
- The I148M variant's effect on fibrosis is independent of its effect on steatosis and inflammation, suggesting direct mechanisms promoting fibrogenesis.
Conclusions:
- The PNPLA3 I148M polymorphism is a critical genetic factor in liver disease progression, acting as a general modifier of fibrogenesis.
- The variant's independent effect on fibrosis suggests mechanisms involving lipid metabolism and non-parenchymal liver cell biology.
- Assessment of the I148M polymorphism may inform future clinical practice and aid in understanding hepatic fibrogenesis mechanisms.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
100
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84